Oxford Biomedica (LON:OXB) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Shares of Oxford Biomedica plc (LON:OXB) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 664.32 and traded as low as GBX 609. Oxford Biomedica shares last traded at GBX 616, with a volume of 220,253 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OXB. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 950 price target on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Jefferies Financial Group began coverage on shares of Oxford Biomedica in a research report on Monday, March 23rd. They set a “buy” rating and a GBX 827 price target for the company. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 687.

Oxford Biomedica Stock Down 1.9%

The firm’s 50-day moving average price is GBX 604.82 and its 200-day moving average price is GBX 664.32. The company has a market cap of £744.86 million, a price-to-earnings ratio of -22.88 and a beta of 1.10. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67.

Oxford Biomedica (LON:OXB) last released its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. Sell-side analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.